Tharimmune (NASDAQ:THAR) Issues Quarterly Earnings Results

Tharimmune (NASDAQ:THAR) issued its quarterly earnings data on Monday. The company reported ($0.99) EPS for the quarter, Zacks reports.

Tharimmune Stock Performance

Shares of Tharimmune stock traded down $0.04 on Monday, hitting $1.48. 3,520 shares of the company’s stock were exchanged, compared to its average volume of 376,421. The company has a 50-day simple moving average of $1.35 and a 200-day simple moving average of $1.85. The stock has a market capitalization of $3.26 million, a PE ratio of -0.15 and a beta of 1.11. Tharimmune has a 1 year low of $0.95 and a 1 year high of $6.39.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).